权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mutagenesis Screen for Prostate Cancer

前列腺癌诱变筛查

基本信息

批准号：
8574446
负责人：
GRANT D TROBRIDGE
金额：
$ 41.78万
依托单位：
WASHINGTON STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-16 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8574446
关键词：
Androgens Bacteria Biological Markers Cancer Etiology Cancer Patient Candidate Disease Gene Castration Cell Culture Techniques Cells Cessation of life Charcoal Chromosomes Databases Detection Disease Progression Distant Environment Epithelial-Stromal Communication Future Gene Expression Gene Expression Profile Genes Growth Human In Vitro Injection of therapeutic agent LNCaP Libraries Location Malignant neoplasm of prostate Mediating Metastatic Prostate Cancer Molecular Mus Mutagenesis Mutate Mutation Neoplasm Metastasis Oncogenes PC3 cell line Parents Plasmids Process Prostate Proteome Proteomics Protocols documentation Proviruses Reverse Transcriptase Polymerase Chain Reaction Risk Screening for Prostate Cancer Serum Shuttle Vectors Site Technology Tumor Suppressor Genes Tumor Suppressor Proteins United States Validation Vascularization Viral Xenograft Model Xenograft procedure anticancer research base cancer genome cancer type candidate identification castration resistant prostate cancer clinically relevant comparative genomic hybridization deep sequencing design gene discovery in vitro Model in vivo knock-down male men new technology new therapeutic target novel outcome forecast overexpression promoter prostate cancer cell prostate cancer model public health relevance small hairpin RNA tumor tumor growth tumor progression vector

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is the second most common cause of cancer related deaths in men, yet relatively little is known about the molecular mechanisms of disease progression. Identifying genes that are involved in this process is important to identify new therapeutic targets. Here we propose to establish a novel retroviral shuttle vector mutagenesis technology to identify genes that drive prostate cancer progression. Comparative genome hybridization (CGH), transcriptome deep sequencing, and proteomics have emerged as technologies for prostate cancer gene discovery. However, distinguishing the causal mutations from the entire cancer genome/transcriptome/proteome remains a challenge. We have developed a novel mutagenesis vector that allows efficient high-throughput identification of candidate dysregulated genes. In this approach, integrated lentiviral shuttle vectors mutagenize target cells by dysregulating the expression of nearby genes. Vector provirus:chromosome junctions are rescued as plasmids in bacteria, and these plasmids are sequenced to identify the chromosomal location of each vector provirus. This identifies nearby candidate dysregulated genes that promote cancer growth and/or progression. Our shuttle vector technology overcomes a severe technical limitation of previous retroviral mutagenesis screens, inefficient PCR-based detection. We will take advantage of an established LNCaP xenograft prostate cancer model to establish our novel technology. Using this technology we expect to rapidly identify novel genes that drive prostate cancer in vivo. These genes can be targeted in future studies to inhibit prostate cancer or used as biomarkers. In future studies our approach may be used for other types of cancer to accelerate the pace of cancer research with broad potential impact.

描述（由申请人提供）：前列腺癌是男性癌症相关死亡的第二大常见原因，但对疾病进展的分子机制知之甚少。识别参与这一过程的基因对于识别新的治疗靶点非常重要。在这里，我们建议建立一种新的逆转录病毒穿梭载体诱变技术，以确定基因驱动前列腺癌的进展。比较基因组杂交（CGH）、转录组深度测序和蛋白质组学已成为发现前列腺癌基因的技术。然而，从整个癌症基因组/转录组/蛋白质组中区分因果突变仍然是一个挑战。我们已经开发了一种新的诱变载体，允许有效的高通量鉴定候选失调基因。在这种方法中，整合的慢病毒穿梭载体通过失调附近基因的表达来诱变靶细胞。载体前病毒：染色体连接在细菌中被拯救为质粒，这些质粒被测序以确定每个载体前病毒的染色体位置。这识别了促进癌症生长和/或进展的附近候选失调基因。我们的穿梭载体技术克服了以前逆转录病毒诱变筛选的严重技术限制，即基于PCR的检测效率低下。我们将利用已建立的LNCaP异种移植前列腺癌模型来建立我们的新技术。使用这项技术，我们希望能够快速识别体内驱动前列腺癌的新基因。这些基因可以在未来的研究中靶向抑制前列腺癌或用作生物标志物。在未来的研究中，我们的方法可能会用于其他类型的癌症，以加快癌症研究的步伐，并产生广泛的潜在影响。